fashion -WSS

fashion

author：Wikipedia 2025-09-06 04:37:16 - browse：78

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Micronoma's microbiome cancer diagnostic approach under fire

WSS

Trump indictment: Who are the 'co

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Telehealth for opioid use disorder is lifesaving

FDA panel endorses Alnylam’s heart drug — after picking it apart

Sage hopes for a blockbuster in antidepressant now before FDA

Scientists inch closer to single

Wikipedia

fashion

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

IRA could hurt research into orphan drugs for rare diseases

Sports medicine is finally prioritizing gender equality

What to expect as Trump is arraigned on his Jan 6. indictment

Drug repurposing or repositioning? The language matters

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Guidelines to prevent youth baseball injuries need more muscle

Diverse clinical trials: Why aren’t we there yet?

After affirmative action ruling, medical educators look to 'holistic review'

What the airline industry can learn from medicine

knowledge

‘Oppenheimer’ and the risks of AI in health care

Acelyrin, a rare IPO success, stumbles in its first big test

Wildfire pollution widens asthma inequities on Long Island

New Covid vaccine is recommended for everyone 6 months or older

National panel will explore requiring free Covid tests

Lawsuit alleges UnitedHealth Group unit illegally denied claims

focus

focus

hotspot

entertainment